Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CRVS
CORVUS PHARMACEUTICALS, INC.
NASDAQ
$14.16
▼ DOWN 3.80% (-0.56)

KEY STATISTICS

Market Cap$1.19 B
52w High$26.95
52w Low$5.58
Dividend Yield—
Frequency—
P/E-23.21
Volume644.53K
Shares Out.84.09M

COMPANY

LEADERSHIP

Richard A. Miller
CHIEF EXECUTIVE
Richard A. Miller

COMPENSATION 2026

Salary$36,566
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$6,000
Total$7,031,566

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 23, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
37

PRICE TARGET

Target High$40.00
Target Low$40.00
Target Median$40.00
Target Consensus$40.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.—
NOV
3
TUE

PRICE

$14.16 ▼ DOWN 3.80% (−$0.56)
$14.00$14.20$14.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM14.16

About Corvus Pharmaceuticals, Inc.

https://www.corvuspharma.com ↗

Corvus Pharmaceuticals, a clinical-stage biopharma in Burlingame, develops immuno-oncology therapies like Mupadolimab, CPI-818, and Ciforadenant, with ongoing trials targeting cancers and collaborations to advance its pipeline.

INDUSTRY

Biotechnology

A PRODUCT CORVUS PHARMACEUTICALS, INC. IS KNOWN FOR

Soquelitinib (CPI-818)
Soquelitinib (CPI-818)

Soquelitinib is an investigational oral drug by Corvus Pharmaceuticals targeting ITK, in clinical trials for immune diseases and cancers, including Phase 3 for T-cell lymphomas and Phase 2 for atopic dermatitis.

COMPETITORS

COMPETITOR
COGT COMPARE
IBRX COMPARE
KYMR COMPARE
PTCT COMPARE
PTGX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
114
LISTED HERE
21
RANKED BY POSITION SIZE
XBI
0.39% · 3.1M
VTI
0.00% · 2.4M
IWM
0.03% · 1.7M
USVM
0.18% · 220.9K
LFSC
1.91% · 170.9K
CANC
0.96% · 142.7K
LABU
0.26% · 113.6K
SBIO
0.61% · 104.1K
XRS2.F
0.03% · 64.4K
PKW
0.04% · 46.1K
FESM
0.01% · 42.1K
RSSL
0.03% · 32.2K
BBC
0.74% · 26.3K
GSSC
0.03% · 21.2K
FSML
0.07% · 7.5K
TILT
0.00% · 4.3K
BIB
0.04% · 3.0K
VETS
0.09% · 1.7K
TNXT
0.04% · 470
USUE.DE
0.00% · 278
RESM
0.03% · 124

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.29%
HOLDERS
240
TOP 12 OF 240 · RANKED BY POSITION SIZE
Orbimed Advisors LLC
7.2M sh · $104.82M
Blackrock, Inc.
7.1M sh · $106.65M
Point72 Asset Management, L.P.
6.5M sh · $47.57M
State Street Corp
4.5M sh · $66.84M
Vanguard Group Inc
3.9M sh · $29.83M
Price T Rowe Associates Inc /Md/
3.8M sh · $56.61M
Morgan Stanley
3.6M sh · $27.47M
Adams Street Partners LLC
3.3M sh · $48.94M
Vivo Capital, LLC
2.8M sh · $41.92M
Bioimpact Capital LLC
2.7M sh · $21.13M
Wellington Management Group Llp
2.7M sh · $40.81M
Rtw Investments, LP
2.7M sh · $19.75M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Moore David Scott
Purchase · 15.0K shares
2026-06-11
★
DIRECTOR
Moore David Scott
Purchase · 21.7K shares
2026-06-11
★
DIRECTOR
van den Broek Richard
Purchase · 15.0K shares
2026-06-11
★
DIRECTOR
CLARK IAN T
Purchase · 15.0K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM Jefferies BUY Barclays OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ABSI$8.71COMPARE
OLMA$10.27COMPARE
VSTM$7.22COMPARE
RGNX$9.66COMPARE
PRTA$9.33COMPARE
CMPX$2.40COMPARE
AKBA$0.88COMPARE
GOSS$0.17COMPARE